156 related articles for article (PubMed ID: 8274406)
21. Deoxyribonucleic acid-binding ability of androgen receptors in whole cells: implications for the actions of androgens and antiandrogens.
Kuil CW; Mulder E
Endocrinology; 1996 May; 137(5):1870-7. PubMed ID: 8612526
[TBL] [Abstract][Full Text] [Related]
22. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
Furr BJ; Tucker H
Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
[TBL] [Abstract][Full Text] [Related]
23. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.
Veldscholte J; Berrevoets CA; Ris-Stalpers C; Kuiper GG; Jenster G; Trapman J; Brinkmann AO; Mulder E
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):665-9. PubMed ID: 1562539
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
25. Ligand-specific dynamics of the androgen receptor at its response element in living cells.
Klokk TI; Kurys P; Elbi C; Nagaich AK; Hendarwanto A; Slagsvold T; Chang CY; Hager GL; Saatcioglu F
Mol Cell Biol; 2007 Mar; 27(5):1823-43. PubMed ID: 17189428
[TBL] [Abstract][Full Text] [Related]
26. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
27. Mutation of the androgen receptor at amino acid 708 (Gly-->Ala) abolishes partial agonist activity of steroidal antiandrogens.
Terouanne B; Nirdé P; Rabenoelina F; Bourguet W; Sultan C; Auzou G
Mol Pharmacol; 2003 Apr; 63(4):791-8. PubMed ID: 12644579
[TBL] [Abstract][Full Text] [Related]
28. Androgenic and antiandrogenic control on epidermal growth factor, epidermal growth factor receptor, and androgen receptor expression in human prostate cancer cell line LNCaP.
Ravenna L; Lubrano C; Di Silverio F; Vacca A; Felli MP; Maroder M; D'Eramo G; Sciarra F; Frati L; Gulino A
Prostate; 1995 Jun; 26(6):290-8. PubMed ID: 7784269
[TBL] [Abstract][Full Text] [Related]
29. Co-activator and co-repressor interplay on the human androgen receptor.
Papaioannou M; Reeb C; Asim M; Dotzlaw H; Baniahmad A
Andrologia; 2005 Dec; 37(6):211-2. PubMed ID: 16336251
[No Abstract] [Full Text] [Related]
30. Studies on the human prostatic cancer cell line LNCaP.
Veldscholte J; Berrevoets CA; Mulder E
J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):341-6. PubMed ID: 8043498
[TBL] [Abstract][Full Text] [Related]
31. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
Le HT; Schaldach CM; Firestone GL; Bjeldanes LF
J Biol Chem; 2003 Jun; 278(23):21136-45. PubMed ID: 12665522
[TBL] [Abstract][Full Text] [Related]
32. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.
Marcelli M; Stenoien DL; Szafran AT; Simeoni S; Agoulnik IU; Weigel NL; Moran T; Mikic I; Price JH; Mancini MA
J Cell Biochem; 2006 Jul; 98(4):770-88. PubMed ID: 16440331
[TBL] [Abstract][Full Text] [Related]
33. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.
Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS
Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797
[TBL] [Abstract][Full Text] [Related]
34. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
Kemppainen JA; Wilson EM
Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
[No Abstract] [Full Text] [Related]
35. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
36. The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins.
Ayub M; Levell MJ
J Steroid Biochem; 1989 Aug; 33(2):251-5. PubMed ID: 2788775
[TBL] [Abstract][Full Text] [Related]
37. Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide.
Wang C; Young WJ; Chang C
Endocrine; 2000 Feb; 12(1):69-76. PubMed ID: 10855693
[TBL] [Abstract][Full Text] [Related]
38. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
39. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells.
Miyamoto H; Yeh S; Wilding G; Chang C
Proc Natl Acad Sci U S A; 1998 Jun; 95(13):7379-84. PubMed ID: 9636157
[TBL] [Abstract][Full Text] [Related]
40. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
Wang LG; Liu XM; Kreis W; Budman DR
Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
